Skip to main content
Premium Trial:

Request an Annual Quote

Cambrex and XCellsyz and Sigma-Aldrich and JRH Biosciences

Premium

Cambrex Buys Immortalized Cell Line Assets from XCellsyz

Cambrex subsidiary Cambrex Bio Science Wokingham will buy conditionally immortalized cell lines and related intellectual property and equipment from British biotech XCellsyz, Cambrex said last week.

Financial terms of the deal were not disclosed.

Two weeks ago, Cambrex signed a worldwide licensing pact with Geron that will see it develop its own immortalized cell lines for distribution using Geron’s human telomerase reverse transcriptase technology (see Inside Bioassays, 1/18/2005). XCellsyz last year had signed a similar agreement for Geron’s telomerase technology, which it used to develop its own immortalized cell lines.

Cambrex said it will use the recently acquired XCellsyz technologies to immortalize a broad set of cell types, which it will sell to researchers for a variety of applications, including cell-based high-throughput drug screening and toxicity testing.


Sigma-Aldrich to Buy JRH Biosciences for $370M

Sigma-Aldrich will acquire JRH Biosciences, a division of CSL Limited, for $370 million in cash, the company said last week.

JRH, headquartered in Lenexa, Kan., supplies cell culture and sera products to the biopharmaceutical industry. It had approximately $150 million in sales in 2004, and was expecting a 10-percent growth in this figure in 2005, Sigma said.

JRH also has manufacturing facilities in the US, Europe, and Australia; and serum collection and processing centers in the US and Australia. It has approximately 400 employees worldwide.

Sigma said that it expects to fund the acquisition with a combination of existing cash, short-term debt, and three-year term debt.

Goldman Sachs acted as financial advisor on the transaction.

 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.